After Structure Therapeutics (GPCR) announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity, Morgan Stanley analyst Terence Flynn argues that 36-week data from the core Phase 2b ACCESS study “appear competitive” with Eli Lilly’s (LLY) orforglipron. The firm, which models an aleniglipron U.S. launch in 2028 and 2040 worldwide unadjusted sales of $6.3B, has an Overweight rating and $120 price target on Structure shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR: